pubmed-article:2984332 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:2984332 | lifeskim:mentions | umls-concept:C0026769 | lld:lifeskim |
pubmed-article:2984332 | lifeskim:mentions | umls-concept:C0025815 | lld:lifeskim |
pubmed-article:2984332 | lifeskim:mentions | umls-concept:C0035020 | lld:lifeskim |
pubmed-article:2984332 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
pubmed-article:2984332 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:2984332 | pubmed:dateCreated | 1985-4-26 | lld:pubmed |
pubmed-article:2984332 | pubmed:abstractText | A randomised comparison is made between methylprednisolone, 1 g intravenously daily for 7 days, and a standard ACTH regime for the treatment of multiple sclerosis in acute relapse. It is found that methylprednisolone produces a more rapid clinical improvement than ACTH but confers no longer term benefit when the two treatments are compared at 3 months. It is proposed that intravenous methylprednisolone does have a role to play in the management of a patient with an acute relapse of multiple sclerosis. | lld:pubmed |
pubmed-article:2984332 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2984332 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2984332 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2984332 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2984332 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2984332 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2984332 | pubmed:language | eng | lld:pubmed |
pubmed-article:2984332 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2984332 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:2984332 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2984332 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2984332 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:2984332 | pubmed:month | Feb | lld:pubmed |
pubmed-article:2984332 | pubmed:issn | 0022-3050 | lld:pubmed |
pubmed-article:2984332 | pubmed:author | pubmed-author:TilleyP JPJ | lld:pubmed |
pubmed-article:2984332 | pubmed:author | pubmed-author:SaundersMM | lld:pubmed |
pubmed-article:2984332 | pubmed:author | pubmed-author:BatemanD EDE | lld:pubmed |
pubmed-article:2984332 | pubmed:author | pubmed-author:NewmanP KPK | lld:pubmed |
pubmed-article:2984332 | pubmed:author | pubmed-author:ClelandP GPG | lld:pubmed |
pubmed-article:2984332 | pubmed:author | pubmed-author:WallsT JTJ | lld:pubmed |
pubmed-article:2984332 | pubmed:author | pubmed-author:BarnesM PMP | lld:pubmed |
pubmed-article:2984332 | pubmed:author | pubmed-author:DickD JDJ | lld:pubmed |
pubmed-article:2984332 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:2984332 | pubmed:volume | 48 | lld:pubmed |
pubmed-article:2984332 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:2984332 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:2984332 | pubmed:pagination | 157-9 | lld:pubmed |
pubmed-article:2984332 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
pubmed-article:2984332 | pubmed:meshHeading | pubmed-meshheading:2984332-... | lld:pubmed |
pubmed-article:2984332 | pubmed:meshHeading | pubmed-meshheading:2984332-... | lld:pubmed |
pubmed-article:2984332 | pubmed:meshHeading | pubmed-meshheading:2984332-... | lld:pubmed |
pubmed-article:2984332 | pubmed:meshHeading | pubmed-meshheading:2984332-... | lld:pubmed |
pubmed-article:2984332 | pubmed:meshHeading | pubmed-meshheading:2984332-... | lld:pubmed |
pubmed-article:2984332 | pubmed:meshHeading | pubmed-meshheading:2984332-... | lld:pubmed |
pubmed-article:2984332 | pubmed:meshHeading | pubmed-meshheading:2984332-... | lld:pubmed |
pubmed-article:2984332 | pubmed:meshHeading | pubmed-meshheading:2984332-... | lld:pubmed |
pubmed-article:2984332 | pubmed:meshHeading | pubmed-meshheading:2984332-... | lld:pubmed |
pubmed-article:2984332 | pubmed:meshHeading | pubmed-meshheading:2984332-... | lld:pubmed |
pubmed-article:2984332 | pubmed:meshHeading | pubmed-meshheading:2984332-... | lld:pubmed |
pubmed-article:2984332 | pubmed:meshHeading | pubmed-meshheading:2984332-... | lld:pubmed |
pubmed-article:2984332 | pubmed:meshHeading | pubmed-meshheading:2984332-... | lld:pubmed |
pubmed-article:2984332 | pubmed:meshHeading | pubmed-meshheading:2984332-... | lld:pubmed |
pubmed-article:2984332 | pubmed:year | 1985 | lld:pubmed |
pubmed-article:2984332 | pubmed:articleTitle | Intravenous methylprednisolone for multiple sclerosis in relapse. | lld:pubmed |
pubmed-article:2984332 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:2984332 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:2984332 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2984332 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2984332 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2984332 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2984332 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2984332 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2984332 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2984332 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2984332 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2984332 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2984332 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2984332 | lld:pubmed |